IPA is a biotherapeutic research and technology company that leverages systems biology, multi-omics modeling, and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. The company represents a HUB of biotherapeutic intelligence that includes a hybrid of experts and technologies, providing highly specialized full-continuum therapeutic antibody discovery and development —with advanced omics and complex artificial intelligence technology [LENSai] that provide greater efficiency and accuracy than ever before. Our mission is to provide the most advanced intelligence and technology to treat disease, bar none. Our goal is to support the advancement of novel biologics against even the most challenging targets, ultimately contributing to the treatment of diseases and the betterment of humankind.